New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes

JAMA

Volumn 280, Issue 1, 1998, Pages 42-48

  Janssen, Robert S ^a   Satten, Glen A ^a,k   Stramer, Susan L ^b,k   Rawal, Bhupat D ^c   O'Brien, Thomas R ^d   Weiblen, Barbara J ^e   Hecht, Frederick M ^g   Jack, Noreen ⁱ   Cleghorn, Farley R ^j   Kahn, James O ^g   Chesney, Margaret A ^h   Busch, Michael P ^c,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b AMERICAN RED CROSS   (United States)

^c Blood Centers of the Pacific   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Medical Research Centre   (Trinidad and Tobago)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k ABBOTT LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABORATORY TEST; PRIORITY JOURNAL; SCREENING TEST; SERODIAGNOSIS; VIRUS DETECTION;

EID: 0032123416     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.1.42     Document Type: Article

References (56)

1. UNAIDS/WHO Working Group on Global HIV/ AIDS and STD Surveillance. Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: World Health Organization; December 1997:1-13.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1997;9(2): 5-43.
3. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324:954-960.
4. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995; 333:408-413.
5. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259: 1749-1754.
6. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-264.
7. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med. 1988;148:945-949.
8. Centers for Disease Control and Prevention. National HIV Serosurveillance Summary: Results Through 1992. Atlanta, Ga: US Dept of Health and Human Services; 1994;3:1-51.
9. Kingsley LA, Zhou SYJ, Bacellar H, et al. Temporal trends in human immunodeficiency virus type 1 seroconversion 1984-1989. Am J Epidemiol. 1991;134:331-339.
10. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA. 1994;271:121-127.
11. Weinstock HS, Sweeney S, Steinberg S, Gwinn M. HIV seroincidence among persons attending sexually transmitted disease (STD) clinics in the United States, 1988-1995. In: Abstracts of the XI International Conference on AIDS; Vancouver, British Columbia; July 7-12, 1996. Abstract Tu.C.2409;1:336.
12. Torian LV, Murrill CS, Makki HA, et al. High HIV seroincidence in nonwhite bisexual men making repeat visits to a New York City sexually transmitted disease clinic, 1994-1995: results of a blinded longitudinal study. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; Washington, DC; January 22-26, 1997. Abstract 177:97.
13. Brookmeyer R, Quinn T, Shepherd M, Mehendale S, Rodrigues J, Bollinger R. The AIDS epidemic in India: a new method for estimating current human immunodeficiency virus (HIV) incidence rates. Am J Epidemiol. 1995;142:709-713.
14. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995;141:166-172.
15. Beyrer C, Brookmeyer R, Natpratan C, et al. Measuring HIV-1 incidence in Northern Thailand: prospective cohort results and estimates based on early diagnostic tests. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:495-499.
16. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35:91-97.
17. Cooper DA, Imrie AA, Penny R. Antibody response to human immunodeficiency virus after primary infection. J Infect Dis. 1987;155:1113-1118.
18. Lange JMA, Parry JV, de Wolf F, Mortimer PP, Goudsmit J. Diagnostic value of specific IgM antibodies in primary HIV infection. AIDS. 1988;2:31-35.
19. McDougal JS, Kennedy MS, Nicholson JKA, et al. Antibody response to human immunodeficiency virus in homosexual men. J Clin Invest. 1987;80:316-324.
20. Lilienfeld AM, Lilienfeld DE. Foundations of Epidemiology. 2nd ed. New York, NY: Oxford University Press; 1976.
21. Enzyme immunoassay for the detection of antibody to human immunodeficiency virus type 1 (HIV-1) in human serum or plasma [package insert]. Abbott Park, Ill: Abbott Laboratories; 1994.
22. Centers for Disease Control. Interpretation and use of the Western blot assay for sero-diagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38(suppl 7):1-7.
23. Cleghorn FR, Jack N, Greenberg M, et al. Primary HIV-1 infection in Trinidad: clinical, immunologic and virologic correlates. Paper presented at: 2nd National Conference on Human Retroviruses and Related Infections; Washington, DC; January 30, 1995. Abstract 14:57.
24. Cleghorn FR, Greenberg M, O'Brien T, et al. A heterosexually transmitted HIV-1 epidemic of subtype B in Trinidad. Paper presented at: 3rd Conference on Retroviruses and Opportunistic Infections; Washington, DC; January 31, 1996. Abstract 509:147.
25. Winkelstein W Jr, Lyman DM, Padian N, et al. Sexual practices and risk of infection by the human immunodeficiency virus: the San Francisco Men's Health Study. JAMA. 1987;257:321-325.
26. Winkelstein W Jr, Samuel M, Padian N, et al. The San Francisco Men's Health Study, III: reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health. 1987;77:685-689.
27. Winkelstein W Jr, Wiley JA, Padian N, et al. The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health. 1988;78: 1472-1474.
28. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames: Iowa State University Press; 1967.
29. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc B. 1977;39:1-38.
30. Silverman BW, Jones MC, Wilson JD, Nychka DW. A smoothed EM approach to indirect estimation problems, with particular reference to sterology and emission tomography. J R Stat Soc B. 1990; 52:271-324.
31. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
32. Zuck TF, Thomson RA, Schreiber GB, et al. The Retrovirus Epidemiology Study (REDS): rationale and methods. Transfusion. 1995;35:944-951.
33. Sayre KR, Dodd RY, Tegtmeier G, Layug L, Alexander SS, Busch MP. False-positive human immunodeficiency virus type 1 Western blot tests in non-infected blood donors. Transfusion. 1996;36:45-52.
34. Chambers JM, Cleveland WS, Kleiner B, Tukey PA. Graphical Methods for Data Analysis. Belmont, Calif: Wadsworth; 1983.
35. Turnbull B. The empirical distribution function with arbitrarily grouped, censored, and truncated data. J R Stat Soc B. 1976;38:290-295.
36. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science. 1991;253:37-42.
37. Bacchetti P, Segal M, Jewell NP. Backcalculation of HIV infection rates. Stat Sci. 1993;8:82-119.
38. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science. 1995;270:1372-1375.
39. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
40. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-461.
41. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;77:1962-1969.
42. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
43. Quinn TC. Acute primary HIV infection. JAMA. 1997;278:58-62.
44. Kahn JO, Walker BD. Acute HIV-1 infection syndrome: a review. N Engl J Med. In press.
45. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in human and animal retrovirus infection. J Infect Dis. 1993;168:1490-1501.
46. Kinloch-de Loës S, de Saussure P, Saurat JH, Stadler H, Hirschel B, Perrin LH. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993; 17:59-65.
47. + T cell responses associated with control of viremia. Science. 1997; 278:1447-1450.
48. Markowitz M, Cao Y, Vesanen M, et al. Recent HIV-1 infection treated with AZT, 3TC, and a potent protease inhibitor. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; Washington, DC; January 22-26,1997. Abstract LB8:207.
49. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998;4:341-345.
50. Conway B, Montessori V, Montaner J, Shillington A, Fransen S, Rouleau D. Use of saquinavir-containing regimens for the treatment of primary HIV infection. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 583:189.
51. Saget B, Goodenow M, Christopherson C, Sninsky J, Kwok S, Scheibel S. Aggressive treatment of recent HIV-1 infected subjects with prolonged undetectable HIV-1 plasma RNA is associated with low levels of HIV-1 proviral DNA. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, Ill; February 1-5, 1998. Abstract 584:189.
52. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995; 122:573-579.
53. O'Brien TR, Busch MP, Donegan E, et al. Heterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners. J Acquir Immune Defic Syndr. 1994;7:705-710.
54. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. JAcquir Immune Defic Syndr. 1994;7:1169-1184.
55. Rothenberg RB, Narramore J. The relevance of social network concepts to sexually transmitted disease control. Sex Transm Dis. 1996;23:24-29.
56. Satten GA. Steady-state calculation of the risk of HIV infection from transfusion of screened blood from repeat donors. Math Biosci. 1997;141:101-113.